Stock PULM PULMATRIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Pulmatrix, Inc.

Equities

PULM

US74584P3010

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.04 USD -1.92% Intraday chart for Pulmatrix, Inc. +2.53% +9.68%
Mar. 28 Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 13 Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
AQ
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
AQ
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
AQ
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
AQ
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
AQ
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
PR
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
AQ
Pulmatrix Supports World Asthma Day 2023
PR
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
AQ
PULMATRIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
PR
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy Asthma and Immunology
AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine for Acute Migraine
AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PULM Stock
  4. News Pulmatrix, Inc.
  5. Press Releases